Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Phase 1/2, Multicenter Study of Belumosudil in Children Aged 1 to <18 Years Requiring Systemic Treatment for Active Moderate-to-severe Chronic Graft Versus Host Disease (cGVHD)

NCT07116031 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT07116031
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07116031 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Phase 1/2, Multicenter Study of Belumosudil in Children Aged 1 to <18 Years Requiring Systemic Treatment for Active Moderate-to-severe Chronic Graft Versus Host Disease (cGVHD)
Lead sponsor
Sanofi
Phase
Phase 2
Overall status
Recruiting
Start date
December 2, 2025
Completion date
February 28, 2031
Enrollment
37 (estimated)
Sites
35

Conditions

As the registry lists them; a condition with its own page is linked.

chronic graft versus host disease